RHHVF ROCHE HOLDINGS AG
- 321.690
- +0.620+0.19%
ROCHE HOLDINGS AG News
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
Roche, Sangamo Ink Licensing Deal for Neuro Drugs
Berenberg Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Raises Target Price to $339.23
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Announces Target Price $252.09
Roche Closes Acquisition of LumiraDx's Point of Care Technology to Expand Access to Diagnostic Testing in Primary Care
Kepler Capital Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Cuts Target Price to $320.4
DZ BANK AG Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating
Goldman Sachs Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Cuts Target Price to $258.57
Express News | Roche Holding H1 Adj. EPS CHF 10.23 Up From CHF 10.10 YoY, Revenue CHF 29.85B Up From CHF 29.78B YoY
Roche Holding Non-GAAP EPS of CHF 10.23, Revenue of CHF 29.85B; Raises FY24 Outlook
Stocks to Watch Next Week: Tesla, Microsoft, Alphabet and Amazon
Kepler Capital Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Cuts Target Price to $318.83
New Data for Roche's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
Novo Nordisk, Eli Lilly Fall on Data From Roche's Weight-loss Pill
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating
Roche's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-term Diabetic Macular Edema (DME) Study
Roche Stock Jumps on Positive Obesity Drug Trial Results
Express News | Roche's Genentech Reveals Phase I Results Of Its Oral GLP-1 Receptor Agonist CT-996 For The Treatment Of People With Obesity
Goldman Sachs Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $256.75
Kepler Capital Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Cuts Target Price to $317.74
Analysis
Price Target
No Data
